_version_ 1866910845756243968
author Gottweis, Juraj
Weng, Wei-Hung
Daryin, Alexander
Tu, Tao
Palepu, Anil
Sirkovic, Petar
Myaskovsky, Artiom
Weissenberger, Felix
Rong, Keran
Tanno, Ryutaro
Saab, Khaled
Popovici, Dan
Blum, Jacob
Zhang, Fan
Chou, Katherine
Hassidim, Avinatan
Gokturk, Burak
Vahdat, Amin
Kohli, Pushmeet
Matias, Yossi
Carroll, Andrew
Kulkarni, Kavita
Tomasev, Nenad
Guan, Yuan
Dhillon, Vikram
Vaishnav, Eeshit Dhaval
Lee, Byron
Costa, Tiago R D
Penadés, José R
Peltz, Gary
Xu, Yunhan
Pawlosky, Annalisa
Karthikesalingam, Alan
Natarajan, Vivek
author_facet Gottweis, Juraj
Weng, Wei-Hung
Daryin, Alexander
Tu, Tao
Palepu, Anil
Sirkovic, Petar
Myaskovsky, Artiom
Weissenberger, Felix
Rong, Keran
Tanno, Ryutaro
Saab, Khaled
Popovici, Dan
Blum, Jacob
Zhang, Fan
Chou, Katherine
Hassidim, Avinatan
Gokturk, Burak
Vahdat, Amin
Kohli, Pushmeet
Matias, Yossi
Carroll, Andrew
Kulkarni, Kavita
Tomasev, Nenad
Guan, Yuan
Dhillon, Vikram
Vaishnav, Eeshit Dhaval
Lee, Byron
Costa, Tiago R D
Penadés, José R
Peltz, Gary
Xu, Yunhan
Pawlosky, Annalisa
Karthikesalingam, Alan
Natarajan, Vivek
contents Scientific discovery relies on scientists generating novel hypotheses that undergo rigorous experimental validation. To augment this process, we introduce an AI co-scientist, a multi-agent system built on Gemini 2.0. The AI co-scientist is intended to help uncover new, original knowledge and to formulate demonstrably novel research hypotheses and proposals, building upon prior evidence and aligned to scientist-provided research objectives and guidance. The system's design incorporates a generate, debate, and evolve approach to hypothesis generation, inspired by the scientific method and accelerated by scaling test-time compute. Key contributions include: (1) a multi-agent architecture with an asynchronous task execution framework for flexible compute scaling; (2) a tournament evolution process for self-improving hypotheses generation. Automated evaluations show continued benefits of test-time compute, improving hypothesis quality. While general purpose, we focus development and validation in three biomedical areas: drug repurposing, novel target discovery, and explaining mechanisms of bacterial evolution and anti-microbial resistance. For drug repurposing, the system proposes candidates with promising validation findings, including candidates for acute myeloid leukemia that show tumor inhibition in vitro at clinically applicable concentrations. For novel target discovery, the AI co-scientist proposed new epigenetic targets for liver fibrosis, validated by anti-fibrotic activity and liver cell regeneration in human hepatic organoids. Finally, the AI co-scientist recapitulated unpublished experimental results via a parallel in silico discovery of a novel gene transfer mechanism in bacterial evolution. These results, detailed in separate, co-timed reports, demonstrate the potential to augment biomedical and scientific discovery and usher an era of AI empowered scientists.
format Preprint
id arxiv_https___arxiv_org_abs_2502_18864
institution arXiv
publishDate 2025
record_format arxiv
spellingShingle Towards an AI co-scientist
Gottweis, Juraj
Weng, Wei-Hung
Daryin, Alexander
Tu, Tao
Palepu, Anil
Sirkovic, Petar
Myaskovsky, Artiom
Weissenberger, Felix
Rong, Keran
Tanno, Ryutaro
Saab, Khaled
Popovici, Dan
Blum, Jacob
Zhang, Fan
Chou, Katherine
Hassidim, Avinatan
Gokturk, Burak
Vahdat, Amin
Kohli, Pushmeet
Matias, Yossi
Carroll, Andrew
Kulkarni, Kavita
Tomasev, Nenad
Guan, Yuan
Dhillon, Vikram
Vaishnav, Eeshit Dhaval
Lee, Byron
Costa, Tiago R D
Penadés, José R
Peltz, Gary
Xu, Yunhan
Pawlosky, Annalisa
Karthikesalingam, Alan
Natarajan, Vivek
Artificial Intelligence
Computation and Language
Human-Computer Interaction
Machine Learning
Physics and Society
Other Quantitative Biology
Scientific discovery relies on scientists generating novel hypotheses that undergo rigorous experimental validation. To augment this process, we introduce an AI co-scientist, a multi-agent system built on Gemini 2.0. The AI co-scientist is intended to help uncover new, original knowledge and to formulate demonstrably novel research hypotheses and proposals, building upon prior evidence and aligned to scientist-provided research objectives and guidance. The system's design incorporates a generate, debate, and evolve approach to hypothesis generation, inspired by the scientific method and accelerated by scaling test-time compute. Key contributions include: (1) a multi-agent architecture with an asynchronous task execution framework for flexible compute scaling; (2) a tournament evolution process for self-improving hypotheses generation. Automated evaluations show continued benefits of test-time compute, improving hypothesis quality. While general purpose, we focus development and validation in three biomedical areas: drug repurposing, novel target discovery, and explaining mechanisms of bacterial evolution and anti-microbial resistance. For drug repurposing, the system proposes candidates with promising validation findings, including candidates for acute myeloid leukemia that show tumor inhibition in vitro at clinically applicable concentrations. For novel target discovery, the AI co-scientist proposed new epigenetic targets for liver fibrosis, validated by anti-fibrotic activity and liver cell regeneration in human hepatic organoids. Finally, the AI co-scientist recapitulated unpublished experimental results via a parallel in silico discovery of a novel gene transfer mechanism in bacterial evolution. These results, detailed in separate, co-timed reports, demonstrate the potential to augment biomedical and scientific discovery and usher an era of AI empowered scientists.
title Towards an AI co-scientist
topic Artificial Intelligence
Computation and Language
Human-Computer Interaction
Machine Learning
Physics and Society
Other Quantitative Biology
url https://arxiv.org/abs/2502.18864